XML 26 R10.htm IDEA: XBRL DOCUMENT v3.26.1
Segments
3 Months Ended
Mar. 31, 2026
Segments  
Segments

4. Segments

The Company views its operations and manages its business in one operating segment, that of the development and commercialization of drugs and antibodies that target critical elements of the immune system. The Company’s Chief Operating Decision Maker (“CODM”) is made up of the Chief Executive Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions and programs that are in line with the Company’s long-term company-wide strategic goals.

The following table presents reportable segment net loss, including significant expense categories, attributable to the Company’s reportable segment for the three months ended March 31, 2026 and 2025 (in thousands):

Three Months Ended

March 31, 

2026

  ​ ​ ​

2025

  ​ ​ ​

Compensation and benefits, excluding stock-based compensation

$

3,027

$

2,239

Stock-based compensation

2,650

 

1,251

Drug manufacturing

431

 

1,830

Clinical trials

5,043

 

1,927

Outside general and administrative

1,244

 

946

Facilities and insurance

558

 

780

Other segment items (1)

1,924

 

949

Total segment expense

14,877

 

9,922

Non-operating income, net

(1,185)

 

(25,115)

Net loss

$

13,692

 

$

(15,193)

(1)Includes consulting, non-clinical research and laboratory supplies.